Type 2 diabetes, thiazolidinediones, and cardiovascular risk. The British journal of general practice : the journal of the Royal College of General Practitioners [Br J Gen Pract] Journal article | | Title | Type 2 diabetes, thiazolidinediones, and cardiovascular risk. | | Author(s) | Taylor C, Hobbs FR | | Institution | Primary Care Clinical Services, University of Birmingham, Birmingham. | | Source | Br J Gen Pract 2009 Jul; 59(564):520-4. | | Abstract | Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achieving adequate glycaemic control is an important aim of therapy. Thiazolidinediones, or glitazones, have been used for the treatment of diabetes for a decade. Rosiglitazone and pioglitazone are currently available, however recent concerns around cardiovascular safety have led to restrictions on their use. Initial trials showed treatments with glitazones improved glycaemic control, however long-term outcomes such as cardiovascular events were not measured. Evidence from more recent trials suggests rosiglitazone is associated with an increased risk of cardiovascular events and both glitazones are associated with higher rates of heart failure. This article discusses the evidence behind these concerns and the most recent guidance on use of thiazolidinediones in clinical practice. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19567003 |
|
|
| |
Advertise on this site.
| | |
|
